Drugs of Today
Overview
Drugs of Today is a scientific journal, published since 1998 in English. The journal's country of origin is Spain and its primary focus area is pharmacology.
Details
Details
Abbr.
Drugs Today (Barc)
Start
1998
End
2023
Frequency
Monthly
p-ISSN
1699-3993
e-ISSN
1699-4019
Country
Spain
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 6461
57
SJR / Ranks: 9977
427
CiteScore / Ranks: 7225
3.70
JIF / Ranks: 5564
1.8
Recent Articles
1.
Kroupova K, Palicka V, Rosa J
Drugs Today (Barc)
. 2023 Feb;
59(3):195-204.
PMID: 36847627
Osteoporosis is a chronic disease with high unmet medical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral...
2.
Wang Z, Xie Y, Wang J, Cheng Y, Fleishman J, Chen Z, et al.
Drugs Today (Barc)
. 2023 Feb;
59(3):179-193.
PMID: 36847626
On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the...
3.
Sakamoto M, Jimeno A
Drugs Today (Barc)
. 2023 Feb;
59(3):169-177.
PMID: 36847625
Nearly two-thirds of patients with non-small cell lung cancer (NSCLC) have locally advanced or metastatic disease at the time of diagnosis, and many patients with early-stage disease will eventually experience...
4.
Simopoulou T, Tsiogkas S, Zafiriou E, Bogdanos D
Drugs Today (Barc)
. 2023 Feb;
59(3):135-167.
PMID: 36847624
In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clinical trials that...
5.
Pilo F, Angelucci E
Drugs Today (Barc)
. 2023 Feb;
59(3):125-134.
PMID: 36847623
Mitapivat, an oral first-in-class activator of erythrocyte pyruvate kinase (PKR), was first investigated in patients with pyruvate kinase deficiency (PKD), where it was found to improve hemoglobin (Hb) concentrations in...
6.
Coco G, Piccotti G, Romano V, Desideri L, Vagge A, Traverso C, et al.
Drugs Today (Barc)
. 2023 Feb;
59(3):113-123.
PMID: 36847622
Dry eye disease (DED) is the most common ocular surface disorder affecting millions of people worldwide. Due to its chronic nature, the management of DED still represents a challenge in...
7.
McCarthy M
Drugs Today (Barc)
. 2023 Feb;
59(3):107-112.
PMID: 36847621
On November 8, 2022, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the interleukin-1 (IL-1) inhibitor anakinra for the treatment of patients with COVID-19...
8.
Mendez A
Drugs Today (Barc)
. 2023 Feb;
59(1):51-59.
PMID: 36811417
The Organization for Professionals in Regulatory Affairs (TOPRA) celebrated its 2022 Annual Symposium, which took place in Vienna, Austria, from October 17 to 19, 2022, to discuss most relevant current...
9.
Liu X, Fang G, Lu H, Shi Z, Chen Z, Han C
Drugs Today (Barc)
. 2023 Feb;
59(1):37-49.
PMID: 36811416
On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic...
10.
Zaborowska-Szmi M, Szmit S, Krzakowski M, Kowalski D
Drugs Today (Barc)
. 2023 Feb;
59(1):17-36.
PMID: 36811415
Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET...